Associations between the uptake of 111In-DTPA-trastuzumab, HER2 density and response to trastuzumab (Herceptin) in athymic mice bearing subcutaneous human tumour xenografts.

Associations between the uptake of 111In-DTPA-trastuzumab, HER2 density and response to trastuzumab (Herceptin) in athymic mice bearing subcutaneous human tumour xenografts.

PURPOSE: The purpose of the study was to investigate the associations between uptake of (111)In-DTPA-trastuzumab, tumour HER2 density and response to trastuzumab (Herceptin) of human breast cancer (BC) xenografts in athymic mice. MATERIALS AND METHODS: The tumour uptake of (111)In-DTPA-trastuzumab...

Fuld beskrivelse

Bibliografiske detaljer
Main Authors:	McLarty, K, Cornelissen, B, Scollard, D, Done, S, Chun, K, Reilly, R
Format:	Journal article
Sprog:	English
Udgivet:	2009

Lignende værker

Micro-SPECT/CT with 111In-DTPA-pertuzumab sensitively detects trastuzumab-mediated HER2 downregulation and tumor response in athymic mice bearing MDA-MB-361 human breast cancer xenografts.
af: McLarty, K, et al.
Udgivet: (2009)

Antitumor effects and normal-tissue toxicity of 111In-nuclear localization sequence-trastuzumab in athymic mice bearing HER-positive human breast cancer xenografts.
af: Costantini, D, et al.
Udgivet: (2010)

The level of insulin growth factor-1 receptor expression is directly correlated with the tumor uptake of (111)In-IGF-1(E3R) in vivo and the clonogenic survival of breast cancer cells exposed in vitro to trastuzumab (Herceptin).
af: Cornelissen, B, et al.
Udgivet: (2008)

In vivo monitoring of intranuclear p27(kip1) protein expression in breast cancer cells during trastuzumab (Herceptin) therapy.
af: Cornelissen, B, et al.
Udgivet: (2009)

Trastuzumab-resistant breast cancer cells remain sensitive to the auger electron-emitting radiotherapeutic agent 111In-NLS-trastuzumab and are radiosensitized by methotrexate.
af: Costantini, D, et al.
Udgivet: (2008)

(111)In-labeled trastuzumab (Herceptin) modified with nuclear localization sequences (NLS): an Auger electron-emitting radiotherapeutic agent for HER2/neu-amplified breast cancer.
af: Costantini, D, et al.
Udgivet: (2007)

Biodistribution and nuclear import of 111In-labeled HIV-1 tat peptide immunoconjugates after intravenous or intratumoural injection in tumour-bearing mice
af: Cornelissen, B, et al.
Udgivet: (2006)

Comparative Effectiveness and Safety of Trastuzumab Biosimilars to Herceptin for Adjuvant Treatment of HER2+ Breast Cancer
af: Caroline Muñoz, et al.
Udgivet: (2024-03-01)

Radiation Recall Reaction Induced by Adjuvant Trastuzumab (Herceptin)
af: Caroline Chung, et al.
Udgivet: (2009-01-01)

Plant-made trastuzumab (herceptin) inhibits HER2/Neu+ cell proliferation and retards tumor growth.
af: Tatiana V Komarova, et al.
Udgivet: (2011-01-01)

Neratinib plus trastuzumab is superior to pertuzumab plus trastuzumab in HER2-positive breast cancer xenograft models
af: Jamunarani Veeraraghavan, et al.
Udgivet: (2021-05-01)

Properties of [(111)In]-labeled HIV-1 tat peptide radioimmunoconjugates in tumor-bearing mice following intravenous or intratumoral injection.
af: Cornelissen, B, et al.
Udgivet: (2008)

Herceptin® (trastuzumab) in HER2-positive early breast cancer: a systematic review and cumulative network meta-analysis
af: Florence R. Wilson, et al.
Udgivet: (2018-11-01)

Olive oil's bitter principle reverses acquired autoresistance to trastuzumab (Herceptin™) in HER2-overexpressing breast cancer cells
af: Brunet Joan, et al.
Udgivet: (2007-05-01)

Cost-minimization analysis comparing subcutaneous trastuzumab at home with intravenous trastuzumab for HER2-positive breast cancer in Singapore
af: Yanting Ouyang, et al.
Udgivet: (2024-11-01)

An Experimental Analysis of the Molecular Effects of Trastuzumab (Herceptin) and Fulvestrant (Falsodex), as Single Agents or in Combination, on Human HR+/HER2+ Breast Cancer Cell Lines and Mouse Tumor Xenografts.
af: Qing Chen, et al.
Udgivet: (2017-01-01)

Multimodal image-guided surgery of HER2-positive breast cancer using [111In]In-DTPA-trastuzumab-IRDye800CW in an orthotopic breast tumor model
af: Marion M. Deken, et al.
Udgivet: (2019-11-01)

Herceptin® (trastuzumab) in HER2-positive early breast cancer: protocol for a systematic review and cumulative network meta-analysis
af: Florence R. Wilson, et al.
Udgivet: (2017-10-01)

Validation of ELISA Test-system for Trastuzumab (Herceptin, Hertikad) quantitative determination in biological fluids
af: V. V. Pisarev, et al.
Udgivet: (2023-05-01)

Chemotherapy-induced cardiotoxic effect in breast cancer patients treated with trastuzumab (Herceptin) by MRI
af: Mohamed Aboulfotouh Mourad, et al.
Udgivet: (2023-12-01)

Long-term trastuzumab (Herceptin®) treatment in a continuation study of patients with HER2-positive breast cancer or HER2-positive gastric cancer
af: Volkmar Müller, et al.
Udgivet: (2018-03-01)

[225Ac]Ac- and [111In]In-DOTA-trastuzumab theranostic pair: cellular dosimetry and cytotoxicity in vitro and tumour and normal tissue uptake in vivo in NRG mice with HER2-positive human breast cancer xenografts
af: Misaki Kondo, et al.
Udgivet: (2023-09-01)

The importance of antibody dependent cell-mediated cytotoxicity (ADCC) for breast cancer response to trastuzumab - Herceptin
af: Juranić Zorica D., et al.
Udgivet: (2002-01-01)

Recommendations for Management of the Trastuzumab (Herceptin) among Iranian Breast Cancer Patients, A Policy Brief
af: Mohammad Reza Rouhollahi, et al.
Udgivet: (2014-04-01)

In silico design, construction and cloning of Trastuzumab humanized monoclonal antibody: A possible biosimilar for Herceptin
af: Soudabeh Akbarzadeh-Sharbaf, et al.
Udgivet: (2012-01-01)

EXPERIENCE WITH SUBCUTANEOUS TRASTUZUMAB USED IN RUSSIAN FEDERATION
af: E. V. Lubennikova, et al.
Udgivet: (2017-11-01)

Effect of Trastuzumab–HER2 Complex Formation on Stress-Induced Modifications in the CDRs of Trastuzumab
af: Baubek Spanov, et al.
Udgivet: (2022-01-01)

Simulating Costs of Intravenous Biosimilar Trastuzumab vs. Subcutaneous Reference Trastuzumab in Adjuvant HER2-Positive Breast Cancer: A Belgian Case Study
af: Steven Simoens, et al.
Udgivet: (2021-05-01)

Novel Toll-like receptor-4 deficiency attenuates trastuzumab (Herceptin) induced cardiac injury in mice
af: Yousif Nasser, et al.
Udgivet: (2011-10-01)

Targeting HER3 or MEK overcomes acquired Trastuzumab resistance in HER2-positive gastric cancer-derived xenograft
af: Mengqi Zhang, et al.
Udgivet: (2022-12-01)

Universal CAR T cells targeted to HER2 with a biotin-trastuzumab soluble linker penetrate spheroids and large tumor xenografts that are inherently resistant to trastuzumab mediated ADCC
af: Lőrinc Nagy, et al.
Udgivet: (2024-03-01)

Formulation of a kit under Good Manufacturing Practices (GMP) for preparing [111In]In-BnDTPA-trastuzumab-NLS injection: a theranostic agent for imaging and Meitner-Auger Electron (MAE) radioimmunotherapy of HER2-positive breast cancer
af: Conrad Chan, et al.
Udgivet: (2022-12-01)

Prática de clínica dos enfermeiros portugueses: administração subcutânea de trastuzumab (herceptin®) e rituximab (mabthera®)
af: Alice Monteiro, et al.
Udgivet: (2018-06-01)

Methotrexate, paclitaxel, and doxorubicin radiosensitize HER2-amplified human breast cancer cells to the Auger electron-emitting radiotherapeutic agent (111)In-NLS-trastuzumab.
af: Costantini, D, et al.
Udgivet: (2010)

Cost-effectiveness analysis of trastuzumab deruxtecan versus trastuzumab emtansine for HER2-positive breast cancer
af: Jiangping Yang, et al.
Udgivet: (2022-09-01)

Subcutaneous Trastuzumab: An Observational Study of Safety and Tolerability in Patients With Early HER2-Positive Breast Cancer
af: Iris Otoya, et al.
Udgivet: (2024-01-01)

In-Trastuzumab Scintigraphy in HER2-Positive Metastatic Breast Cancer Patients Remains Feasible during Trastuzumab Treatment
af: Sietske B.M. Gaykema, et al.
Udgivet: (2014-07-01)

Termination of trastuzumab in HER2-positive metastatic breast cancer patients who received trastuzumab beyond progression
af: Izzet Dogan, et al.
Udgivet: (2023-05-01)

Quantification of Trastuzumab–HER2 Engagement In Vitro and In Vivo
af: Alena Rudkouskaya, et al.
Udgivet: (2020-12-01)

Augmented inhibition of angiogenesis by combination of HER2 antibody chA21 and trastuzumab in human ovarian carcinoma xenograft
af: Zhang Anli, et al.
Udgivet: (2010-08-01)